Peace the announcement says it all...../saves ANP a mulitude of money and opens BIGGER DOORS....
ATL1102’s mode of action in targeting the VLA-4 receptor and its therapeutic profile suggests that it has potential to treat SP-MS patients. As support for this, the monoclonal antibody drug Tysabri®, which also targets VLA-4, has been shown in Phase II clinical trials to benefit patients with progressive forms of MS. Tysabri® is currently undergoing Phase III trials in SP-MS with results due this year. Positive results would be an important validating event for ATL1102 potentially adding further value and therefore would be expected to spark more pharmaceutical company interest in ATL1102.
ANP Price at posting:
9.6¢ Sentiment: Buy Disclosure: Held
